MedTrace Logo

Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

NCT02063997 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2018-01-29

No results posted yet for this study

Summary

The purpose of this study is to determine whether arhalofenate is effective in preventing flares and reducing serum uric acid in gout patients.

Conditions

Interventions

DRUG

Arhalofenate 600 mg

Arhalofenate 600 mg tablets once daily for 12 weeks

DRUG

Allopurinol 300 mg

Allopurinol 300 mg tablets once daily for 12 weeks

DRUG

Colchicine 0.6 mg

Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks

DRUG

Placebo

Placebo tablets once daily for 12 weeks

DRUG

Arhalofenate 800 mg

Arhalofenate 800 mg tablets once daily for 12 weeks

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States
  • Canada
  • Georgia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02063997 on ClinicalTrials.gov